Try our Advanced Search for more refined results

ENDO PHARMACEUTICALS INC. et al v. FEDERAL TRADE COMMISSION

  1. October 29, 2018

    Judge Lets FTC Slip Allergan's Suit, But Rips Venue Conduct

    A Pennsylvania federal judge Monday dismissed litigation by Watson Laboratories Inc. and Allergan Finance LLC that sought the court's declaration that the Federal Trade Commission lacks authority to bring a pay-for-delay generic drug suit, while blasting the commission's decision to refile in California as an act of "apparent forum shopping."

  2. January 31, 2018

    FTC Looks To Beat Suit Challenging Its Authority

    The Federal Trade Commission on Tuesday renewed its bid to toss a suit challenging its authority to pursue a pay-for-delay case against Watson Laboratories Inc., telling a Pennsylvania federal judge the case is an improper attempt to preempt an enforcement action.

  3. June 08, 2017

    FTC Fights Watson's Bid To Block Lidoderm Antitrust Suit

    The Federal Trade Commission renewed its opposition Wednesday to Watson Laboratories' bid for a ruling that the agency lacks the authority to pursue a pay-for-delay suit against it over pain relief patch Lidoderm, telling a Pennsylvania federal court that the drugmaker's legal interpretation would keep the FTC from challenging assorted large-scale frauds.

  4. June 01, 2017

    No Basis For FTC Lidoderm Pay-For-Delay Suit, Watson Says

    The Federal Trade Commission maintains it has the authority to pursue a pay-for-delay suit over pain relief patch Lidoderm against Watson Laboratories Inc. in federal court, but its allegations should be heard in an administrative proceeding, Watson told a Pennsylvania federal court Wednesday.

  5. May 10, 2017

    Watson Seeks Quick Win In Suit Over FTC Litigation Powers

    Watson Laboratories Inc. asked a Pennsylvania federal court Tuesday to rule that the Federal Trade Commission doesn't have the authority to sue the drugmaker for past alleged pay-for-delay settlements that are no longer in force.

  6. March 17, 2017

    FTC Can't Dodge Ruling On Litigation Authority, Watson Says

    The U.S. Federal Trade Commission's attempt to do away with a suit challenging its authority to bring litigation in federal court is based on a misreading of the facts and should be disregarded, Watson Laboratories Inc. told a Pennsylvania federal court Thursday.

  7. March 02, 2017

    Challenge To FTC Authority Belongs In Calif., Agency Says

    The U.S. Federal Trade Commission on Thursday asked a Pennsylvania federal court to dismiss a lawsuit by Watson Laboratories and Allergan challenging its authority to bring lawsuits over past behavior, saying the companies should raise the objection in an ongoing pay-for-delay case in California.

  8. January 30, 2017

    FTC Deceived Court On Pay-For-Delay Suit, Watson Says

    The U.S. Federal Trade Commission has misled a Pennsylvania federal court about its plans to refile a pay-for-delay lawsuit against Watson Laboratories Inc. to dodge questions about its authority to bring the suit, and the court should consider claims challenging that authority, Watson said Friday.

  9. January 03, 2017

    FTC Wants Endo's Challenge To Its Litigation Power Nixed

    The U.S. Federal Trade Commission has asked a Pennsylvania federal court to dismiss a suit by Endo Pharmaceuticals Inc. seeking a ruling on the agency's authority to file lawsuits over behavior that occurred in the past, saying several courts have rejected similar attempts to hamper the FTC's power.

  10. October 27, 2016

    Endo Seeks Ruling On FTC Ability To Sue Over Past Conduct

    Endo Pharmaceuticals Inc. has asked a Pennsylvania federal court to rule on whether the U.S. Federal Trade Commission can sue in federal court over conduct that has occurred in the past, an issue in its ongoing antitrust dispute with the agency over the drugs Opana ER and Lidoderm.